TON - August 2013 Vol 6 No 7

TON - August 2013 Vol 6 No 7 — September 4, 2013
Vanderbilt University School of Nursing is affiliated with Vanderbilt University School of Medicine and the Ingram Cancer Center, one of the National Cancer Institute (NCI)–designated Centers of Excellence. Read More ›

TON - August 2013 Vol 6 No 7 — September 4, 2013
With the growing number of cancer survivors in the United States and around the world, supportive care has become of even greater importance for these patients. Read More ›

TON - August 2013 Vol 6 No 7 — September 4, 2013
Advanced melanoma has re-mained an intractable malignancy for decades, with dacarbazine the only approved therapy and high-dose interleukin-2 limited by significant toxicity. Read More ›

TON - August 2013 Vol 6 No 7 — September 4, 2013
The announcement this spring by Angelina Jolie that she had undergone a risk-reducing double mastectomy after learning she carried a mutation in the BRCA1 gene, as well as the recent US Supreme Court decision on gene patenting, has resulted in an influx of questions to both genetic providers and support organizations about hereditary breast cancer. Read More ›

TON - August 2013 Vol 6 No 7 — September 4, 2013
In last month’s issue of The Oncology Nurse-APN/PA (TON), we published a letter from Cindy Covington. Cindy, an infusion nurse from Georgia, was responding to MMA’s “The Devil Is in the Details” column (see the TON April issue). MMA discussed how some of her needs as a hospitalized patient were not met and she thought her nurses should be able to help. Read More ›

TON - August 2013 Vol 6 No 7 — September 4, 2013
At the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, several sessions focused on recent advances in melanoma, including new ways to boost the activity of current therapies, the development of a new class of immunotherapy, and a new form of immunotherapy—an oncolytic vaccine. Read More ›

TON - August 2013 Vol 6 No 7 — September 4, 2013
Protecting the skin from the sun should be considered a year-round necessity because our skin is constantly exposed to the sun’s ultraviolet rays and is thus susceptible to melanoma. Read More ›

TON - August 2013 Vol 6 No 7 — September 4, 2013
Sorafenib has become the first drug in years to prove effective in the treatment of differentiated thyroid cancer (DTC) that has become resistant to radioactive iodine (RAI), according to phase 3 study results reported at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting. Read More ›


Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: